54.80 +0.39 (0.72%)
After hours: 6:27PM EDT
|Bid||54.50 x 800|
|Ask||54.80 x 800|
|Day's Range||51.38 - 56.55|
|52 Week Range||6.76 - 74.81|
|Beta (3Y Monthly)||0.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On CNBC's "Mad Money Lightning Round," Jim Cramer said this is a great level to buy more shares of Tandem Diabetes Care Inc (NASDAQ: TNDM ). Cramer is not a buyer of Electronic Arts Inc. (NASDAQ: ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Mid-caps stocks, like Tandem Diabetes Care, Inc. (NASDAQ:TNDM) with a market capitalization of US$3.6b, aren’t the focus of m...
Investors have plenty more to like about Tandem Diabetes (NASDAQ: TNDM) stock after the company reported its fiscal-fourth-quarter results on Feb. 26. TNDM stock reached $74.81 last month and is now trading around $62. Those who missed the run-up of TNDM may want to examine the company's recent earnings to determine how much more Tandem stock can rise.Source: Tandem Diabetes TNDM earned 2 cents per share of Tandem stock, as its revenue jumped 132.3% to $3.7 million. Its operating margin came in at 1%, the first time that metric has been positive, signaling that it will be profitable in the intermediate term. * 10 Medical Marijuana Stocks to Cure Your Portfolio TNDM grew thanks to the successful launch of Basal-IQ. According to diaTribe, Basal IQ is an "algorithm" which "stops basal insulin delivery when low blood sugar is predicted (within 30 minutes) and resumes insulin delivery once blood sugar levels start to rise."InvestorPlace - Stock Market News, Stock Advice & Trading TipsTNDM successfully transitioned Johnson & Johnson's (NYSE: JNJ) customers to its product. For the year, TNDM's revenue grew to $184 million, up over 70% from 2017. Never has Tandem grown this fast on an annual basis. GuidanceLooking ahead, Tandem forecast 2019 sales of $255 million - $270 million and break-even EPS. It expects its gross margin to be around 52% in full-year 2019. In the very competitive industry of medical electronics, TNDM is doing very well.The company transitioned successfully from a domestic-focused startup to a global diabetes-technology company. Given the strong momentum it's expected to have this year, TNDM may become a big global player.Management is unsure of its pricing strategy for its automated insulin delivery system, Control-IQ. The company has a priority of securing reimbursement for the product from health-insurance companies. Building a Stronger TeamTNDM has added strong executives to its leadership team. Rick Valencia, the President of Qualcomm Life, joined Tandem's board last year. In Q1, Becky Robertson also joined its board, bringing her proven track record of helping medical-device companies. She also has a great deal of experience as an engineer, entrepreneur, corporate executive, and board member. Manuel Jaime became Senior VP of Technology and Digital Health. He brings expertise in mobile connectivity and cloud technology. Growth OpportunityThe FDA's approval of Tandem's T:slim X2, an ACE or alternate controller-enabled infusion pump, which features a touch screen and has the ability to receive feature updates remotely, greatly widens Tandem's lead over other medical-devices firms. Not only will remote delivery lower operating costs, but customers will enjoy the ease of upgrading their devices.The results speak for themselves: shipments of the device grew by over 100% last year. And what is more impressive is that TNDM has no debt and has positive-operating-cash flow. New ProductsTandem is positioned for another strong year. It has a differentiated pump platform, an automated insulin delivery program, and will expand internationally this year. Surveys already show that Tandem's customers are more satisfied than those who have bought insulin pumps made by other manufacturers.Design testing of Tandem's t:sport insulin pump, which is half the size of the t:slim and has a mobile control, will be mostly completed this year. Once the device receives ACE pump classification in the second half of the year, it will be submitted for CE marking in 2020. Tandem's Mobile AppTNDM is scheduled to launch its first-ever mobile app in the first half of this year. Since it will be offered on both major platforms, Apple and Android, the app should increase customers' satisfaction. It will also give healthcare providers easier access to pump and blood glucose data. The Valuation and Fair Value of TNDM StockAnalysts are highly bullish on TNDM stock, according to Tipranks. But that has mixed implications for TNDM stock, since, if too many mainstream investors buy Tandem stock, its valuations will become stretched. But on the other hand, the fact that Wall Street has few red flags on Tandem stock is positive for TNDM. The Bottom Line on TNDM StockTandem stock has paused after rallying strongly in March. TNDM stock could continue to be profitable for investors as the company carries out its growth plans.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * 7 A-Rated Healthcare Stocks for Industry Expansion * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever Compare Brokers The post Why Tandem Diabetes Stock Will Rally Much Further appeared first on InvestorPlace.
Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.
Worries over an inverting yield curve, a solid predictor of future recessions, caused investors to worry last week. However, they are having trouble pinning down whether it's a natural function of the bond market or a circumstance of artificially low global rates and a Fed that's been raising short-term rates. Let's use that to lead into our top stock trades for Tuesday. Top Stock Trades for Tomorrow 1: Bank of AmericaBank of America (NYSE:BAC) was hammered last week on these yield inversion worries. Right as the stock was breaking out beautifully over $29.50, shares tumbled back below resistance and cratered toward $28 support.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, that level didn't provide much help, as BAC quickly fell below $27 last week. After consolidating those losses, shares are showing some life now back above $28.50 and BAC is looking much better. * The Elite 8 Stocks to Buy for Massive Outperformance It's not out of the woods yet, though. Bulls need to see $28 hold as support. Preferably, it can move higher and close above the 50-day moving average later this week. But limiting our risk is key and that means holding $28. If that fails, $27.50 and last week's lows are possible. If it holds, $29.50 resistance is back on the table. Top Stock Trades for Tomorrow 2: NetflixNetflix (NASDAQ:NFLX) continues to slowly chop higher, putting in a series of higher lows and higher highs (purple arrows). $380 is proving to be a key level and should shares breakout over this mark, a run to $400 is possible.Channel support and the 50-day moving average are key right now. A close below this mark puts a retest of the 200-day back on the table. Keep it simple. Top Stock Trades for Tomorrow 3: IntelThis $54 to $55 level has been notable in the past for Intel (NASDAQ:INTC). If Nvidia (NASDAQ:NVDA), Advanced Micro Devices (NASDAQ:AMD) and other chip makers can remain hot, bulls will certainly be looking for a breakout in INTC over this level.If it does, it certainly puts the prior highs near $56 in play, while Intel has rather quietly been performing quite well. If resistance holds up, look for a buying opportunity near uptrend support/the 50-day moving average. More aggressive bulls can buy a test-and-hold of the 20-day moving average. Top Stock Trades for Tomorrow 4: Activision BlizzardWedbush analysts named Activision Blizzard (NASDAQ:ATVI) one of its best ideas on Monday, helping the stock to a 3% gain on the day. After hitting a low near $40 in February, shares have been steadily trending higher, putting in a series of higher lows.It's now above its 50-day and 20-day moving averages and a close over $48 could really ignite this name. If it can, $55 is a potential upside target, while a run to the 200-day could eventually be in the cards after some consolidation.However, if this stock loses the $45 level and the 50-day, it could be in trouble. The decline below $40 didn't pan out, but keep in mind, the 200-week moving average is up near $50. Top Stock Trades for Tomorrow 5: Tandem Diabetes CareWhile the rest of the market is enjoying nice gains on the day, Tandem Diabetes Care (NASDAQ:TNDM) is not. Shares are down almost 6% on Monday -- and more losses could be on the way.The late-February gap-up open came near $60 and this level has buoyed the stock several times since. However, the 20-day moving average is now acting as resistance, while uptrend support is down near $57.50. The downside targets then include the 50-day and the gap-fill down near $50. * 5 Cannabis Stocks Set to Skyrocket -- According to Wall Street's Top Analysts In the short-term and on the long side, I need to see $50 hold as support and TNDM close above the 20-day to be interested in buying.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVDA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately Compare Brokers The post 5 Top Stock Trades for Tuesday: BAC, NFLX, ATVI, INTC appeared first on InvestorPlace.
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
"We did like it when it was at $140, $150 -- but what's happened is that it's just literally up 40 straight points [since then]," Cramer said during an exclusive video-conference call for members of his Action Alert PLUS club for investors. Cramer, whose charitable trust already owns AAPL, recommended against putting new money into the stock despite recent upgrades or positive comments about the stock from Bank of America, Morgan Stanley and Cowen. Cramer said Apple should buy Tandem and Dexcom, whose systems can display your blood-glucose levels on an Apple Watch or iPhone.
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Blickenstaff added that Tandem has taken a consumer electronics approach to diabetes management, making sleek, stylish products. The latest technology and algorithms do most of the work managing insulin, leaving the patient to mostly just monitor the results.
Tandem Diabetes Care (NASDAQ:TNDM) shot higher after surpassing earnings and revenue estimates. TNDM stock ended its string of losses and announced that COO John Sheridan would assume the CEO position on March 1. Current CEO Kim Blickenstaff will become Executive Chairman.Source: Tandem Diabetes However, this places Tandem Diabetes Care stock in an awkward position. The monopoly power that comes with its latest pump should ensure revenue growth for years to come.However, an unprecedented run from penny-stock status to just above $62 per share over the last year makes a near-term pullback more likely. The move higher over the previous year means TNDM stock belongs on watch lists. However, I would wait for a pullback before putting it in a portfolio.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Best Stocks to Buy on U.S.-China Trade Optimism The NumbersTNDM stock rose by more than 27% in morning trading following its earnings beat and surprise profit. The San Diego-based firm reported a profit in the fourth quarter of $3.7 million, or two cents per share. Analysts had expected a loss of 20 cents per share.Quarterly revenue also significantly surpassed estimates, coming in at $76.2 million. This represents an 89.1% increase from year-over-year levels when the company reported revenues of $40 million. Wall Street had previously predicted $56.34 million for the quarter. A 133% increase in the sales of pumps bolstered this increase.Results for the full-year yielded similar positive surprises. TNDM reported revenues of $183.9 million, a 71% increase over the $107.6 million reported in 2017. However, net losses came in much higher for the year. In 2018, the company lost $122.6 million. Still, that factors in a $66.5 million non-cash charge and a $5.3 million loan repayment.The company also guided higher for 2019. The company predicts it will bring in between $225 million and $270 million in revenue. Analysts had previously forecasted $219.48 million. Although they declined to predict earnings, they do forecast that adjusted EBITDA will break even. Analysts forecast a 75-cent per share loss for fiscal 2019. TNDM Stock Has Gone to ExtremesThese improving prospects cap off a wild run for TNDM stock over the last five years. TNDM had fallen from a peak of over $300 per share in early 2014 to just over $2 per share by the fall of 2017. In 2016, TNDM stock tanked as United Health (NYSE:UNH) chose Medtronic (NYSE:MDT) insulin products over its own. Mounting losses and cash concerns weighed on the stock over the next two years.However, the outlook for the company improved last year when the FDA approved a system which combines Tandem's pump with a glucose monitor made by DexCom (NASDAQ:DXCM). This patent-protected solution helps protect people with Type-1 diabetes from dangerous highs and lows in insulin levels. It also gives Tandem a product monopoly that has caused an unprecedented rise in TNDM stock. Today's surge takes Tandem from penny-stock levels to over $59 per share in the last year alone. The TNDM Stock ConundrumStill, the very factors that have lifted TNDM stock have also made buying the equity difficult. The stock rose by 1,509% in 2018. The post-earnings bump means the increase so far in 2019 comes close to 65%. Without question, the future looks promising. It remains a question of how promising.Even before the company issued higher guidance, TNDM traded at more than 12 times sales. Moreover, despite the quarterly profit, analysts expect annual losses through 2021.I think TNDM will become profitable in time. I also believe the stock will continue to rise in the long run. However, in the near-term, this has come too far too fast. I would not discourage those who want TNDM stock from buying in at some point. Still, I would wait for a pullback. The Bottom Line on TNDM StockThe factors driving the long-term success of Tandem Diabetes Care stock have placed TNDM stock in an uncertain position for now. TNDM soared higher in morning trading as the company beat revenue and earnings estimate. Higher guidance and changes at the top level also bolstered the stock.I see TNDM stock as a lucrative long-term opportunity. The monopoly power coming from its latest pump will bring continued revenue growth. Moreover, placing John Sheridan in the CEO position and moving Kim Blickenstaff to the board of directors engenders stability amid the personnel changes.However, investors need to remember that TNDM stock has grown from penny-stock levels to more than $62 per share over the last year. With an elevated price-to-sales ratio and annual profits still out of reach, a near-term pullback remains a distinct possibility.The company's monopoly ensures Tandem will become one of the more essential medical equipment companies. As a result, TNDM stock will trade at higher levels years from now. However, with the near-term picture more uncertain, I do not see now as the time to buy.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 5 STARS Stocks That Continue to Define the Future * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio * 5 Real Estate Stocks to Buy for Dividend Income Compare Brokers The post Wait for the Inevitable Pullback to Buy TNDM Stock appeared first on InvestorPlace.
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.